75F40122A00018↗
Deloitte Consulting LLP received this contract vehicle from Fda Office of Acq Grant Svcs, Food and Drug Administration: $0 obligated so far for special studies/analysis- regulatory. It runs to 2027-09-29.
Key facts · data as of Oct 25, 2026
- Recipient
- Deloitte Consulting LLP
- Awarding agency
- Food and Drug Administration (Department of Health and Human Services)
- Contracting office
- Fda Office of Acq Grant Svcs (75F401)
- Obligated to date
- $0
- Potential value
- $30.81M
- Ends
- 2027-09-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75F40122A00018, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_IDV_75F40122A00018_7524
Deloitte Consulting LLP: all federal awards · Department of Health and Human Services: spending · Fda Office of Acq Grant Svcs: what it buys · The follow-on: recompete brief
DRUG LABELING INITIATIVE BPA
Up for re-bid: ends 2027-09-29. Recompete brief →
What it is
- Product or service
- Special Studies/Analysis- Regulatory (PSC B528)
- Industry
- All Other Professional, Scientific, and Technical Services (NAICS 541990)
- Contracting office
- Fda Office of Acq Grant Svcs (75F401)
- Pricing
- Order dependent (set on each order)
- How it was bought
- Contract vehicle (IDV) itself
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Orders under this vehicle
11 orders worth $28.43M (current value). The largest:
- 75F40126F19011 · $11.32M · ends 2027-09-19
- 75F40126F19012 · $5.69M · ends 2027-09-29
- 75F40126F19008 · $1.81M · ends 2026-11-29
- 75F40125F19007 · $1.75M · ends 2026-01-30
- 75F40126F19010 · $1.52M · ends 2027-09-29
- 75F40124F19005 · $1.52M · ends 2025-03-31
- 75F40126F19013 · $1.50M · ends 2027-09-29
- 75F40123F19002 · $1.48M · ends 2024-06-30
- 75F40126F19009 · $1.43M · ends 2027-08-20
- 75F40123F19004 · $252.7K · ends 2024-07-02
- 75F40124F19006 · $163.1K · ends 2027-09-29
Every action
4 actions since 2023-09-06. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-12-15 | P00004 | Option exercised | $0 | DRUG LABELING INITIATIVE BPA |
| 2025-03-27 | P00003 | Option exercised | $0 | DRUG LABELING INITIATIVE BPA |
| 2024-01-15 | P00002 | Option exercised | $0 | DRUG LABELING INITIATIVE BPA |
| 2023-09-06 | P00001 | Option exercised | $0 | DRUG LABELING INITIATIVE BPA |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗